CAMBRIDGE, Mass.CAMBRIDGE, Mass. — The Food and Drug Administration is attaching a black box warning to the Vertex Pharmaceuticals hepatitis C treatment Incivek over a potentially fatal rash. The FDA ...

Last February, the FDA nixed Vertex’s bid to expand cystic fibrosis med Kalydeco to patients with specific mutations in the CFTR gene. On Wednesday, though, the Cambridge drugmaker finally got what it ...

Vertex Pharmaceuticals Incorporated VRTX announced that its type II variation marketing authorization application (“MAA”) for its triple combo cystic fibrosis (“CF”) drug, Kaftrio, has been validated ...